Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
about
The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer.Economics of the clinical management of lung cancer in France: an analysis using a Markov model.The cost of lung cancer in Alberta.
P2860
Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
@ast
Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
@en
type
label
Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
@ast
Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
@en
prefLabel
Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
@ast
Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
@en
P2860
P356
P1476
Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6690426
P407
P577
1999-05-01T00:00:00Z